Date: 28/05/2018

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Sub: Outcome of Board Meeting held on 28th May, 2018.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 28th May, 2018 and transacted following business:

1. Approved Audited financial results for the quarter and year ended on 31st March, 2018. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Audited Financial results for the quarter and year ended on 31st March, 2018 along with Audit Report issued by the Statutory Auditors of the company.
2. Approved allotment of 1,00,000 Equity shares under Vivo Bio Employees Stock Option Scheme, 2016(VBESOS, 2016), who have exercised their options.

The Meeting started at 5.00 PM and ended at 8:30 PM

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

Vivo Biotech Limited Hyderabad

M Kalyan Ram
Whole Time Director
DIN: 02012580

Statement of Audi

S.No.	PARTICULARS
I	Revenue from operations
II	Other income
III	**Total Inccome**
IV	**Expenses**
	a) Increase/(decrease) in stock in trade and WIP
	b) Consumption of Raw materials
	c) Purchase of traded goods
	d) Employees Cost
	e) Depreciation and amortisation
	f) Finance Cost
	g)Administrative Expenditure
V	Profit before Exceptional and Extraordinary Items and Tax
VI	Exceptional items
VII	**Profit before Extraordinary Items and Tax**
VIII	Extraordinary Items
IX	**Profit before tax**
X	Tax Expense
	a. Current Tax
	b. Deffered tax
XI	**Profit for the Period from continuing activities**
XII	Profit/(loss) from discontinuing operations
XIII	Tax expense of discontinuing operations
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XII
XV	**Profit (Loss) for the period (XI + XIV)**
XVI	Other Comprehensive Income
	a.Items that will not be reclassified to profit or loss (Net of Ta
	b.Items that will be reclassified to profit or loss (Net of Tax)
	Total other Comprehensive Income
XVII	**Total Comprehensive Income(XV+XVI)**
XVIII	Paid Up Share Capital (Face value of Rs.10/-)
XIX	**Earnings per equity share:**
	1)Basic
	2)Diluted

Place: Hyderabad
Dated:28/05/2018

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

Statement of Assets and Liabilities			In Rupees
	Particulars	As AT 31/03/2018 Audited	As AT 31/03/2017 Audited
A	ASSETS		
1	**Non-Current Assets**		
	Fixed Assets		
	Property, Plant and Equipment	211,165,340	228,419,540
	Capital Work-In-Progress	39,442,795	29,603,205
	Intangible Assets	63,506,021	55,317,336
	Financial A ssets		
	Non-Current Investments	300,000	300,000
	Other Non Current Assets	390,553	261,106
	Total Non-Current Assets	**314,804,709**	**313,901,187**
2	**Current Assets**		
	Inventories	75,862,445	45,585,882
	Financial Assets		
	Trade Receivables	117,764,845	76,658,708
	Cash and cash equivalents	41,451,949	11,845,177
	short term loans and advances	40,012,515	44,618,597
	Other current assets	5,385,610	18,744,387
	Total Current Assets	**280,477,364**	**197,452,751**
	TOTAL ASSETS	**595,282,073**	**511,353,938**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	Equity Share Capital	98,505,200	93,505,200
	Other Equity	73,820,202	32,477,351
	Money Received Against Share Warrants	21,000,000	
	Total Equity	**193,325,402**	**125,982,551**
2	**Liabilities**		
	Non Current liabilities		
	Financial Liabilities		
	Borrowings	138,981,330	209,323,034
	Defered Tax Liabilities(Net)	5,624,369	7,817,914
	Long term provisions	3,058,239	2,502,805
	Total Non Current Liabilities	**147,663,938**	**2[illegible]3,753**

Notes

1. The Company has adopted IND AS with effect from 01st April,2017 with comparatives being restated. Accordingly impact of the of transition has been provided in the previous year's quarterly and year ended results
2. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 28th May,2018.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required
4. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 will be published in Newspaper.
5. The figures for the current quarter are the balancing figures between the Audited

Standalone Reconciliation of Profit after Tax as per GAAP and IAS (Rs. In Lakhs)		
Particulars	Quarter ending 31st March,2017	Year ending 31st March,2017
Profit after Tax as per Indian GAAP	(526,293.00)	25,038,792.00
Other Comprehensive Income		
Add:		
Items that will not be reclassified to P&L Account (Net of Tax)	28,172.25	112,689.00
Total Other Comprehensive Income	**28,172.25**	**112,689.00**
Profit after Tax as per IAS	**(498,120.75)**	**25,151,481.00**

Standalone Reconciliation of Profit after Tax as per GAAP and IAS (Rs. In Lakhs)		
Particulars	Equity as at 31st March, 2017	Equity as at 01st April,2016
Other Equity reported under GAAP	32,364,662	7,325,870
Adjustments	112,689	-
Other Equity reported under IND AS	**32,477,351**	**7,325,870**

Vivo Biotech Limited Hyderabad

P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of M/s. VIVO BIO TECH LTD. pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

To
The Board of Directors
VIVO BIO TECH LTD.

1. We have audited the quarterly financial results of **M/s. Vivo Bio Tech Limited** for the quarter ended March 31, 2018 and to the year to date financial results for the year ended March 31, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, except for the disclosures regarding Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2018 and the published year-to-date figures up to December 31, 2017, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2018 have been prepared on the basis of the annual IND AS financial Statements for the nine-month period ended December 31, 2017, the audited annual financial statements as at and for the year ended March 31, 2018, and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial results for the nine-month period ended December 31, 2017 which was prepared in accordance with applicable Ind AS and other recognised accounting policies laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rules 7 of the companies (Accounts) Rules 2014 and other accounting principles generally accepted in India and our audit of the annual financial statements as at and for the year ended March 31, 2018; and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

2. These financial results have been prepared on the basis of Ind AS financial statements and reviewed quarterly financial results up to the end of the third quarter, which are the responsibility of Companies Management. Our responsibility is to express an opinion on these financial results based on our Audit of such annual Ind AS Financial statements, which has been prepared in accordance with the recognised and measurements principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act, 2013 and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

Date: 28/05/2018

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Declaration Pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulation,2015.

Sub: Declaration for Unmodified opinion

Ref: Script Code# 51150

I,M Kalyan Ram, Whole Time Director of the Company , hereby declare that the Statutory Auditors of the Company M/s. P.C.N.& Associates, Chartered A